Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis

@inproceedings{Li2017MorinPP,
  title={Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis},
  author={Bin Li and Xunbo Jin and Huilin Meng and Bo Hu and Tao Zhang and Jiang Yu and Shaoan Chen and Xudong Guo and Weiguo Wang and Wei Jiang and Jinzhi Wang},
  booktitle={Oncotarget},
  year={2017}
}
Paclitaxel is a first-line microtubule-stabilizing drug in treating prostate cancer. However, most patients develop resistance and experience relapse. Morin (3,5,7,20,40-pentahydroxyflavone) is an anti-tumor flavonoid in a numerous types of cancer cells including breast, ovarian and lung cancers. We therefore researched the effects of morin as an adjuvant to paclitaxel in in treating DU145 and PC-3 cells in vitro and DU145 derived prostate cancers in nude mice models. The chemosensitivities of… CONTINUE READING
Highly Cited
This paper has 493 citations. REVIEW CITATIONS
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

494 Citations

0200400600201720182019
Citations per Year
Semantic Scholar estimates that this publication has 494 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 38 references

Morin: A Promising Natural Drug.

Current medicinal chemistry • 2016
View 1 Excerpt

How Taxol/paclitaxel kills cancer cells

Molecular biology of the cell • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…